Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial.

Saved in:
Bibliographic Details
Title: Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial.
Authors: Osei-Tutu L; Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana., Kariuki SK; Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya., Lee CK; PATH's Center for Vaccine Innovation and Access, Washington, DC, USA., Fabre R; GSK, Wavre, Belgium., Bii DK; Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya., Adjei S; Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana., Oneko M; Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya., Attobrah Sarfo MA; Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana., Ockenhouse CF; PATH's Center for Vaccine Innovation and Access, Washington, DC, USA., Schuerman L; GSK, Wavre, Belgium., Buabeng PBY; Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana., Bakari A; Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana., Atieno C; Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya., Kotoh-Mortty MF; Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana., Otieno K; Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya., Ntiamoah Y; Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana., Sang T; Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya., Bollaerts A; GSK, Wavre, Belgium., Westercamp N; Malaria Branch, Division of Parasitic Diseases and Malaria, National Center for Emerging Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Ansong D; Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana., Agbenyega T; Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana., Samuels AM; Malaria Branch, Division of Parasitic Diseases and Malaria, National Center for Emerging Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Malaria Branch, Division of Parasitic Diseases and Malaria, National Center for Emerging Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Kisumu, Kenya., Ofori-Anyinam O; GSK, Wavre, Belgium. Electronic address: opokua.ofori-anyinam@gsk.com.
Corporate Authors: RTS,S study group
Source: The Lancet. Global health [Lancet Glob Health] 2025 Oct; Vol. 13 (10), pp. e1723-e1736.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101613665 Publication Model: Print Cited Medium: Internet ISSN: 2214-109X (Electronic) Linking ISSN: 2214109X NLM ISO Abbreviation: Lancet Glob Health Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2214-109X
DOI:10.1016/S2214-109X(25)00272-4